We bring you the latest news from the healthcare about the health care in the United Kingdom.

vrijdag 2 november 2018

The Lancet: [News] 60th ASTRO Annual Meeting

[News] 60th ASTRO Annual Meeting
Daniel Gomez (MD Anderson Cancer Center, Houston, TX, USA) presented the final results of a randomised, phase 2 trial in which patients with stage IV non-small-cell lung cancer with oligometastases were randomly assigned to receive local consolidative therapy (chemoradiotherapy or resection) followed by subsequent standard maintenance treatment/observation or to standard maintenance treatment/observation alone. The primary endpoint of progression-free survival was previously reported to be improved with local consolidative therapy.
Read more

[News] European Society of Medical Oncology 2018 Congress
Jaume Capdevila Castill√≥n (Vall d'Hebron Institute of Oncology, Barcelona, Spain) presented the results of a phase 2 trial of the multikinase inhibitor levatinib, in patients with advanced pancreatic (n=55) and gastrointestinal (n=56) neuroendocrine tumours (NETs). The primary endpoint—objective response—was achieved by 29% patients overall (40% pancreatic NETs; 18·5% gastrointestinal NETs). At a median follow-up of 11 months, median progression-free survival (PFS) was 14·2 months (95% CI 11·4–not reached [NR]) in patients with pancreatic NETs and 17·6 months (11·5–NR) in gastrointestinal NETs.
Read more

[News] Surveillance imaging of Wilms' tumours
A retrospective analysis has shown that overall survival in patients with recurrent unilateral Wilms' tumours did not improve when recurrence was detected with CT scans, compared with detection based on chest x-ray and abdominal ultrasound (CXR/US).
Read more

[News] Maintenance olaparib in advanced ovarian cancer
A new study has found that maintenance therapy with the PARP inhibitor olaparib significantly improves progression-free survival in patients with newly diagnosed BRCA1/2-mutated advanced ovarian cancer.
Read more

[Articles] Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial
We define a whole chromosomal signature that allows the assignment of non-WNT/non-SHH medulloblastoma patients normally classified as standard-risk into favourable-risk and high-risk categories. In addition to patients younger than 16 years with WNT tumours, patients with non-WNT/non-SHH tumours with our defined whole chromosomal aberration signature and patients with SHH-TP53wild-type tumours should be considered for therapy de-escalation in future biomarker-driven, risk-adapted clinical trials.
Read more